Abstract
Purpose
Antimicrobial agents are frequently prescribed during pregnancy. This study aims to explore the association between antimicrobial exposure and pregnancy outcomes.
Patients and Methods
A multi-center retrospective cohort study of pregnant patients (n=370) was conducted in 22 tertiary hospitals in China. Adverse pregnancy outcomes and admission of neonate to neonatal intensive care unit (NICU) were considered as outcomes. The effect of antimicrobial exposure on pregnancy outcomes was assessed using a multivariate logistic regression model.
Results
Use of first-generation cephalosporins during pregnancy was associated with a significantly higher risk of adverse pregnancy outcomes (odds ratio [OR]: 3.64 [95% confidence interval, CI: 1.43–9.24], P = 0.007) and admission of neonate to the NICU (OR: 3.41, 95% CI: 1.37–8.53, P=0.009) compared with use of third-generation cephalosporins, after adjusting for gestational age of exposure to antimicrobial agents, cesarean section, and antimicrobial dose. Similarly, a higher risk of adverse pregnancy outcomes (OR: 14.76, 95% CI: 4.43–49.11) and neonatal NICU admission (OR: 11.74, 95% CI: 3.59–38.35) were observed among women with first-generation cephalosporins use compared with mothers with no antimicrobial use.
Conclusion
Both first- and third-generation cephalosporins use was associated with an increased risk of adverse pregnancy and neonatal outcomes. In addition, first-generation cephalosporins were associated with an increased risk of those pregnant and neonatal outcomes, when compared with third-generation cephalosporins. We should require to determine the indications and contraindications for use of cephalosporins during pregnancy.
Highlights
The retrospective cohort study showed effects of antimicrobial on pregnant women.
Cephalosporins were the most commonly used antimicrobial drugs during pregnancy.
Use of first-generation cephalosporins was risky for adverse pregnancy outcomes.
Ethical Approval Statement
This research was approved by the Ethics Committee of Department of Obstetrics and Gynecology affiliated to Fudan University (2020-131). All data are available at the ResMan Manager of Chinese Clinical Trial Registry (Registration number: ChiCTR2100044398). Informed consents were obtained.
Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
Disclosure
There are no conflicts of interest to disclose.